HyOrc Corporation announced independent lab results showing their commercial module produces syngas with 75.43% combined hydrogen and carbon monoxide and only 0.76% nitrogen, a significant improvement over conventional methods. This low nitrogen content enhances efficiency and reduces equipment needs. The first commercial module is set for deployment in Portugal in early 2027, aiming to convert 3 tonnes of refuse-derived fuel daily into about 1 tonne of methanol. The company plans to expand capacity with a €6.7 million grant supporting a larger facility producing 8 tonnes of methanol daily.
HyOrc Corporation's syngas production results provide context for energy sector trends. For readers following energy stocks, 18 of 79 priced US energy stocks on Pluang rose while 58 fell. Notable movers include UEC at USD 7.87 (+2.08%), PTEN at USD 13.01 (-2.33%), and APA at USD 51.62 (-2.30%) as of Nov 02, 2026 20:02 WIB.
The global bio-based construction polymer market, valued at $18.2 billion in 2025, is projected to grow to $35 billion by 2033 at an 8.3% CAGR. Growth is fueled by rising demand for sustainable building materials that reduce greenhouse gas emissions ...
Annual Over-the-Air (OTA) software updates for software-defined vehicles (SDVs) are projected to reach over 2 billion globally by 2035, up from 546 million in 2025, driven by rising SDV sales and advanced vehicle software platforms. Level 3 and above...
Fram Wind Solutions AS, a joint venture partly owned by BW Offshore, secured a NOK 1.94 billion grant from Enova to develop a floating offshore wind project featuring two 18.5 MW turbines, the largest globally, with a combined capacity of 37 MW. The ...
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
